Doctors were hopeful the drug, which was being tested in a large clinical trial by Novartis, was going to be a powerful new tool to fight heart disease.

Traditional gene editing rewrites DNA. But a new approach, called epigenome editing, aims to treat the molecular scars we collect throughout our lives.

Artificial intelligence was used to help develop a drug candidate, rentosertib, for a rare lung condition. Its maker says the drug also seems to reduce the biological hallmarks of age.

Artificial intelligence was used to help develop a drug candidate, rentosertib, for a rare lung condition. Its maker says the drug also seems to reduce the biological hallmarks of age.

The preliminary research was conducted in mice, but scientists were optimistic the results would apply to humans. Clinical trials begin this month.